Publications by authors named "James Barter"

Claim this Profile
T
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
Christof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, John K Chan, Nicoline Raaschou-Jensen, James F Barter

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Robert W Holloway, Premal Thaker, Alberto A Mendivil, Sarfraz Ahmad, Ahmed N Al-Niaimi, James Barter

Int J Gynecol Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic counseling and testing for hereditary cancer risk in young adult women: Facilitating autonomy and informed decision making is key.
Beth N Peshkin, Susan T Vadaparampil, Lindsey M Hoskins, Suzanne M O'Neill, James F Barter

Gynecol Oncol Rep· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.
Scott McMeekin, Don Dizon, James Barter, Giovanni Scambia, Lyudmila Manzyuk

Gynecol Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of robotic, laparoscopic, and abdominal myomectomy in a community hospital.
Joseph M Gobern, C J Rosemeyer, James F Barter, Albert J Steren

JSLS· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
Robert L Coleman, Alan Gordon, James Barter, Steven Sun, Wayne Rackoff

Oncologist· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous abdominal fascial closure: a randomized controlled trial of poly(L-lactide/glycolide).
James W Orr, Fredrick J Montz, James Barter, Steven D Schaitzberg, James E Delmore

Gynecol Oncol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Visible-regime polarimetric imager: a fully polarimetric, real-time imaging system.
James D Barter, Harold R Thompson, Christine L Richardson

Appl Opt· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asymptomatic postmenopausal simple ovarian cyst.
Yinka Oyelese, Angela S Kueck, James F Barter, Ivica Zalud

Obstet Gynecol Surv· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits and costs of using HPV testing to screen for cervical cancer.
Jeanne S Mandelblatt, William F Lawrence, Sharita Mizell Womack, Denise Jacobson, Bin Yi, James Barter

JAMA· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis